Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Pedro Villardi"'
Autor:
Alan Rossi Silva, Clara Alves Silva, Felipe de Carvalho Borges da Fonseca, Pedro Villardi, Susana Rodrigues Cavalcanti van der Ploeg
Publikováno v:
Sur: International Journal on Human Rights, Vol 18, Iss 31, Pp 107-117 (2021)
The Covid-19 pandemic has increased the inequality of rights around the world. The intellectual property system contributes to this asymmetry by limiting access to vaccines and other health technologies to only a few producers. This article address
Externí odkaz:
https://doaj.org/article/1211db6aef824683b126035de0289917
Autor:
Rosângela Caetano, Marilena Cordeiro Dias Villela Correa, Pedro Villardi, Paulo Henrique Almeida Rodrigues, Claudia Garcia Serpa Osorio-de-Castro
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0247853 (2021)
BackgroundThis study examines the dynamics of the eculizumab patenting, orphan designation, and marketing authorization process in different countries and regulatory systems and analyzes drug revenues since its first marketing authorization.MethodsA
Externí odkaz:
https://doaj.org/article/b41a9f5b76e84e3c820302e74e1988e0
Autor:
Rosângela Caetano, Paulo Henrique Almeida Rodrigues, Marilena C Villela Corrêa, Pedro Villardi, Claudia Garcia Serpa Osorio-de-Castro
Publikováno v:
Revista de Saúde Pública, Vol 54 (2020)
ABSTRACT OBJECTIVES This study examined the purchases of eculizumab, a high-cost monoclonal antibody used in the treatment of rare diseases by Brazilian federal agencies, in terms of purchased quantities, expenditures, and prices. METHODS Eculizumab
Externí odkaz:
https://doaj.org/article/e681dcc7d6b044158e2e1f3f17244eaa
Autor:
Pedro Villardi, Felipe Fonseca
Publikováno v:
Homa Publica, Vol 1, Iss 2 (2017)
Acesso a medicamentos e patentes farmacêuticas têm sido alvo de intensos debates, principalmente a partir da criação da OMC e da assinatura do Acordo TRIPS, no início dos anos 1990. Em uma aliança estratégica, países desenvolvidos e corporaç
Externí odkaz:
https://doaj.org/article/f6fef6a8a18249bcb97fd371244c78f9
Publikováno v:
Intellectual Property Law and Access to Medicines ISBN: 9781003176602
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77d4c5c05f3269a82d04ddbc8a3646a5
https://doi.org/10.4324/9781003176602-20
https://doi.org/10.4324/9781003176602-20
Autor:
Rosângela Caetano, Claudia Garcia Serpa Osorio-de-Castro, Paulo Henrique de Almeida Rodrigues, Pedro Villardi, Marilena Correa
Publikováno v:
Revista de Saúde Pública
Revista de Saúde Pública, Vol 54 (2020)
Revista de Saúde Pública v.54 2020
Universidade de São Paulo (USP)
instacron:USP
Revista de Saúde Pública, Volume: 54, Article number: 22, Published: 02 MAR 2020
Revista de Saúde Pública, Vol 54 (2020)
Revista de Saúde Pública v.54 2020
Universidade de São Paulo (USP)
instacron:USP
Revista de Saúde Pública, Volume: 54, Article number: 22, Published: 02 MAR 2020
OBJECTIVES This study examined the purchases of eculizumab, a high-cost monoclonal antibody used in the treatment of rare diseases by Brazilian federal agencies, in terms of purchased quantities, expenditures, and prices. METHODS Eculizumab purchases
Autor:
Rosângela Caetano, M.C. Corrêa, Claudia Garcia Serpa Osorio-de-Castro, Pedro Villardi, Paulo Henrique de Almeida Rodrigues
Publikováno v:
Value in Health Regional Issues. 19:S75
Autor:
Pedro Villardi
Publikováno v:
Physis, Vol 28, Iss 1 (2018)
Physis: Revista de Saúde Coletiva, Volume: 28, Issue: 1, Article number: e280107, Published: 24 MAY 2018
Physis: Revista de Saúde Coletiva v.28 n.1 2018
Physis
Universidade do Estado do Rio de Janeiro (UERJ)
instacron:UERJ
Physis: Revista de Saúde Coletiva, Volume: 28, Issue: 1, Article number: e280107, Published: 24 MAY 2018
Physis: Revista de Saúde Coletiva v.28 n.1 2018
Physis
Universidade do Estado do Rio de Janeiro (UERJ)
instacron:UERJ
Resumo O artigo aborda o problema do acesso aos medicamentos ARVs e a construção da agenda de lutas do movimento social da AIDS, especificamente o caso do tenofovir, suas pró-drogas e a combinação com a emtricitabina. Discute de que estratégias